Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTuHURA Biosciences reports Q1 2026 financial results and corporate update
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
medium
TuHURA disclosed first quarter 2026 financial results through a press release on May 15, 2026. The 8-K filing references the results but does not include specific financial figures in the body.
Item 2.02 verify on EDGAR → -
low
The company furnished an investor presentation under Regulation FD rules for use in meetings with investors and analysts. This is a routine disclosure mechanism to ensure fair information sharing.
Item 7.01 verify on EDGAR →
Summary
TuHURA Biosciences filed an 8-K to announce its first quarter 2026 financial results and provide a corporate update. The filing itself is procedural, with the actual financial details contained in an attached press release rather than in the 8-K body. This is a standard quarterly reporting practice for biotech companies.
The company also furnished an investor presentation that will be used in ongoing meetings with analysts and investors. This presentation was filed under Regulation FD, which requires companies to publicly disclose any material information they share privately with select investors.
For retail investors, the key action item is to review the attached press release (Exhibit 99.1) for the actual Q1 financial figures, cash position, and any updates on clinical trial progress or pipeline developments. The investor presentation may provide additional context on the company's strategic direction.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
TuHURA Biosciences reported Q1 2026 financial results and provided a corporate update via press release on May 15, 2026.
Added in current filing · verify on EDGAR →
On May 15, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended March 31, 2026, and providing a corporate update.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures or corporate update details, which are provided in the attached press release exhibit.
Event · Item 7.01 — Regulation FD Disclosure
TuHURA furnished an investor presentation under Regulation FD; no material business event disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company is also furnishing in this Current Report on Form 8-K a presentation (the “Investor Presentation”) that may be used by the Company at various meetings with investors, analysts, or others from time to time.
The company filed an investor presentation (Exhibit 99.2) under Regulation FD for use in meetings with investors and analysts. This is a routine disclosure mechanism that allows companies to share information publicly while complying with fair disclosure rules. The presentation may be updated from time to time.
Event · Item 9.01 — Financial Statements and Exhibits
TuHURA Biosciences filed an 8-K attaching a press release and investor presentation dated May 2026, with no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1 Press Release, dated May 15, 2026
99.2 Investor Presentation, dated May 2026
The company filed an 8-K attaching two exhibits: a press release dated May 15, 2026 and an investor presentation dated May 2026. The filing body provides no details about the content or purpose of these materials, making it impossible to assess materiality without reviewing the actual exhibits.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify